egnite Brings Renowned Interventional Cardiologist, Rahul Sharma, onto Executive Team as Senior Medical Advisor

egnite Brings Renowned Interventional Cardiologist, Rahul Sharma, onto Executive Team as Senior Medical Advisor

ALISO VIEJO, Calif. – February 16, 2023 –  egnite, Inc., a leading digital-health company in the field of cardiovascular care, is proud to announce the appointment of Rahul P. Sharma, MD, MBBS, FRACP, as its new Senior Medical Advisor.

A renowned interventional cardiologist, Sharma brings a wealth of knowledge and expertise to egnite’s executive team. With over a decade of experience in structural heart disease and transcatheter valve therapy, Sharma will play a key role in shaping egnite’s clinical strategy, advancing the organization’s mission to improve patient care through digital health technologies.

Sharma has a proven track record of success in advancing the field of cardiovascular medicine as an investigator in several national multi-center clinical trials and as a co-author of numerous peer-reviewed scientific articles. As Senior Medical Advisor, Sharma will help shape the real-world evidence strategy for egnite, working closely with healthcare providers to drive improved patient care and outcomes through egnite’s innovative technologies. Sharma will also drive key product evolutions as he advises egnite on technology enhancements that support best-in-class cardiovascular programs and help generate progressive clinical science that advances medicine.  

“We are thrilled to welcome Rahul to the egnite team,” said Joel Portice, CEO of egnite. “His extensive experience and deep knowledge of the clinical landscape will be invaluable as we develop and launch innovative solutions to improve patient outcomes.”

Based in the heart of Silicon Valley, Sharma has fused his passion for science and innovation by working in collaboration with several health tech companies. He is also a co-founder of Synchron, a leading implantable brain-computer interface company looking to restore the lives of patients with neurological diseases. Sharma is currently the Director of Structural Interventions, Associate Director of the Cardiac Catheterization Laboratory, and the Associate Professor of Medicine at a large academic institution.

“I am excited to join the egnite team during the next phase of growth for the company,” said Sharma. “I am committed to using my expertise to improve patient outcomes and make a meaningful difference in the lives of those we serve.”

About egnite, Inc.

egnite is a visionary digital health company born from the innovation of Edwards Lifesciences, committed to advancing the health of our society through innovative cardiovascular solutions. egnite uses AI-driven algorithms and big data to produce business intelligence for healthcare, elevating the role of data in critical decisions. The company partners with leading hospitals and life sciences providers to transformative care delivery for cardiovascular patients. The company is based in Aliso Viejo, Calif., for more information, visit www.egnitehealth.com.

Related Articles

AI Alliance

What the EARLY TAVR Trial Data Could Mean for Already Busy Heart Teams 

On the heels of the exciting EARLY TAVR data and egnite’s Acute Valve Syndrome in Aortic Stenosis study, both led by Dr. Philippe Genereux, we’ve been asked by several cardiovascular (CV) administrators what a potential change in the management of asymptomatic severe aortic stenosis (SAS) patients could mean for their already busy heart teams.